Levetiracetam Sandoz (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates the release of neurotransmitters. By stabilising neuronal firing and decreasing excitatory neurotransmission, it lowers the likelihood of abnormal electrical activity that leads to seizures.

The specific dose of Levetiracetam Sandoz is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Only a qualified healthcare professional should set the dosing regimen.

Safety data for levetiracetam in pregnancy are limited, and the medication should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should discuss possible infant exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancing agents such as valproate. It is generally well‑tolerated, has few drug‑enzyme interactions, and can be used as monotherapy or adjunct therapy, making it a versatile option in epilepsy management.

Levetiracetam Sandoz tablets should be stored at room temperature, below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

Levetiracetam Sandoz is taken orally, usually with or without food. Tablets should be swallowed whole with water and not crushed or chewed unless specifically directed by a healthcare professional.

Serious risks include severe allergic reactions such as rash or swelling, mood alterations like depression or suicidal thoughts, and rare blood disorders such as neutropenia or thrombocytopenia. Patients should seek immediate medical attention if they experience any of these symptoms.

Patients with known hypersensitivity to levetiracetam or any of the tablet’s excipients should avoid the medication. Additionally, individuals with severe renal impairment may require dose adjustments, and clinicians should evaluate suitability on a case‑by‑case basis.